Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (CGC -5.95%) and Novavax (NVAX 0.92%). 1. Canopy GrowthCanopy Growth emerged as a leader in the cannabis industry toward the end o ...

Core Viewpoint - The article highlights the potential investment opportunities in healthcare companies Merck and Bristol Myers Squibb, which are currently undervalued due to company-specific challenges but have strong long-term prospects. Group 1: Merck - Merck is nearing the loss of patent exclusivity for its key drug Keytruda, which is expected to face biosimilars by the end of the decade [4] - Despite the challenges, Merck's subcutaneous version of Keytruda has shown positive phase 3 results, potentially extending its patent exclusivity into the next decade [5] - The subcutaneous formulation is easier and faster to administer, reducing patient and physician time in the administration process by 49.7% and 45.7% respectively [6] - Merck has a strong pipeline with new approvals, including Winrevair and Enflonsia, and offers a reliable dividend program [7][8] - The stock's forward price-to-earnings ratio is 9.1, significantly lower than the healthcare industry average of 16.3, indicating potential upside for long-term investors [8] Group 2: Bristol Myers Squibb - Bristol Myers Squibb is facing patent expiration for its cancer drug Opdivo and has already lost exclusivity for Revlimid and Sprycel [9] - The company reported a 6% year-over-year revenue decline to $11.2 billion in the first quarter, but its growth portfolio saw a 16% increase in sales to $5.6 billion [11] - BMS has received recent approvals, including a subcutaneous version of Opdivo, which will help mitigate losses from biosimilar competition [10] - The company has a robust pipeline and is expected to secure additional approvals, positioning it to navigate current challenges [12] - Bristol Myers Squibb's stock is undervalued with a forward P/E ratio of 7, suggesting strong long-term return potential despite a 17% decline this year [13]

Core Viewpoint - Burcon NutraScience Corporation is set to showcase its innovative Chipotle Black Bean Protein Hummus at the IFT FIRST Annual Event & Expo, highlighting its advancements in plant-based protein technology [1][6]. Group 1: Product Innovation - The Chipotle Black Bean Protein Hummus is crafted using Burcon's proprietary triple blend of Peazazz®C pea protein, Puratein®C canola protein, and Solatein™ sunflower protein, resulting in a dip that is both flavorful and nutritious [6][8]. - Burcon's plant-based proteins boast over 90% purity, neutral flavor, and smooth mouthfeel, making them suitable for various food applications [6][9]. Group 2: Event Details - The IFT FIRST event will take place in Chicago from July 13-16, 2025, where Burcon will be located at booth S4066 [1][6]. - Attendees will have the opportunity to sample the Chipotle Black Bean Protein Hummus during a special tasting event on July 14 and 15, from 11:00 AM to 1:00 PM [7][9]. Group 3: Company Background - Burcon NutraScience is recognized as a global leader in high-performance plant-based proteins, with a strong commitment to sustainability and innovation in the food and beverage industry [11]. - The company holds an extensive patent portfolio covering novel proteins derived from various plant sources, positioning itself as a key player in the growing plant-based market [11].

Our whole foundation, our core of our media policies is to to reach the broadest audience. And so, how do we do that. We have to extend beyond our current platforms.YouTube is a great platform, global platform. Uh, and it'll be uh, you know, in front of the wall, so it's free to everybody on a global basis. It's a great way for us to share our game with a global audience.And it's it's what we're trying to do now is reach the fans where they are. I think you see in a lot of these new platforms, different dem ...

Business leaders from around the globe attending Allen and Company's annual conference in Sun Valley, Idaho this week. Our Julia Borston is there this morning. Beautiful shot and has a special guest.Hey, JB. Good morning, Carl. That's right.I'm here in Sun Valley and I'm joined by NFL Commissioner Roger Goodell. Commissioner, thanks so much for joining us here. Thanks for having me, Julia.Um, so some big news. You have a new YouTube exclusive game um in the first week of the season. The season is less than ...

In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "This vaccine not only offers broad protection against canine influenza but also integrates seamlessly into our Tru Portfolio. Our commitment ...

Core Viewpoint - ZyVersa Therapeutics, Inc. has entered into a warrant inducement agreement with an institutional investor, which includes the immediate exercise of existing warrants and the issuance of new warrants at a reduced exercise price of $0.67, generating approximately $2.0 million in gross cash proceeds for working capital and corporate purposes [1][2]. Group 1 - The agreement involves the immediate exercise of Series A-2 Warrants for up to 957,200 shares and Series A-3 Warrants for up to 2,105,265 shares at an exercise price of $0.67 [1]. - The investor will receive new Series A-4 Warrants to purchase up to 6,124,930 shares, which will be exercisable upon stockholder approval and will expire five years from that date [2]. - The transaction is expected to close on or about July 9, 2025, pending customary closing conditions [2]. Group 2 - A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction [3]. - The new warrants were offered in a private placement under an exemption from the registration requirements of the Securities Act, and the company plans to file a registration statement with the SEC for the resale of common stock upon exercise of the new warrants [4]. Group 3 - ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases, utilizing proprietary technologies such as Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100 [6].

Core Viewpoint - Zhejiang University Second Affiliated Hospital (ZUSAH) has established a closed-loop ecosystem of "clinical needs - scientific research innovation - results transformation - patient benefits" in the practice of the "Healthy China" strategy, achieving high performance in national evaluations for six consecutive years [2] Group 1: Innovation in Medical Technology - ZUSAH has initiated independent research and development in the field of cardiac intervention, leading to the creation of domestic transcatheter aortic valve replacement products that significantly improve surgical precision and patient outcomes while reducing medical costs [2][3] - The hospital has developed an AI-assisted diagnostic system for coronary heart disease, which streamlines the entire process from outpatient screening to surgical planning, addressing the complexities and high costs of traditional assessment methods [3][4] Group 2: Integration of Research and Clinical Practice - ZUSAH emphasizes the integration of clinical challenges into scientific research, aiming to convert clinical problems into research questions and ultimately benefiting patients through innovative solutions [4][5] - The hospital has established a clinical research special fund and an "innovation center" model, focusing on multidisciplinary collaboration to tackle major diseases like valvular heart disease and coronary heart disease [5] Group 3: Future Aspirations and Goals - ZUSAH aims to cultivate versatile talents who can both treat patients and conduct research, ensuring that clinical research outcomes possess both scientific rigor and translational value [5] - The hospital is committed to addressing unanswered questions in the medical field and hopes to develop more innovative medical devices and technologies to serve patients in the future [5]

One of my “things to watch today” announcing integration of Mythos Chain (Polkadot eco parachain) MYTH token in their dex.Not exactly sure how the crosschain swaps will work here (still need to read more) but the timing is funny.I predict in a year or so, most crosschain friction will be completely abstracted away, making UX so much better than what we’ve had for the last decade. Gud tekBlackhole (@BlackholeDex):Gaming continues to innovate, and Mythos is a prime example of it!We're partnering with @Enterth ...

Core Insights - Novo Nordisk (NVO) has achieved significant growth driven by the success of its semaglutide-based therapies, Wegovy and Ozempic, while also diversifying into rare blood disorders [1][9] Product Portfolio - Key marketed hemophilia therapies include NovoSeven and Esperoct, contributing incremental revenues [2] - Alhemo has recently been approved in the EU for hemophilia A or B with inhibitors, although it is not yet approved in the U.S. [3] - The company is evaluating Mim8 in a late-stage program for hemophilia A, with regulatory submission anticipated in 2025 [4] Competitive Landscape - Eli Lilly (LLY) generates substantial revenue from its tirzepatide medicines and has a diverse product range across various therapeutic areas, including oncology and immunology [5] - Merck (MRK) is also expanding its therapeutic reach beyond its flagship oncology drug Keytruda, with new products expected to generate significant long-term revenues [6] Stock Performance and Valuation - Year-to-date, Novo Nordisk shares have declined by 19.6%, underperforming the industry and the S&P 500 [7][8] - The company's shares trade at a forward price/earnings ratio of 16.31, higher than the industry average of 15.09, but below its five-year mean of 29.25 [10] Earnings Estimates - Earnings estimates for 2025 have improved from $3.89 to $3.93 per share, while 2026 estimates have decreased from $4.76 to $4.58 [15] - The stock's return on equity is 80.95%, significantly higher than the industry average of 33.55% [18]